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Background: Several controlled trials report similar short-term clinical outcome of polymer-free drug-eluting stents compared with polymer-based 
drug-eluting stents. However, the long-term safety and efficacy in the high-risk subpopulation of patients with diabetes mellitus has not yet been 
extensively investigated. This study reports the 5-year results of the LIPSIA Yukon trial which randomized 236 patients with diabetes mellitus to a 
polymer-free sirolimus-eluting stent (Yukon Choice, Translumina, n=120) versus a polymer-based paclitaxel-eluting stent (Taxus Liberté, Boston 
Scientific, n=116) and had previously shown no significant difference in clinical outcome at 9 months.
methods: A structured telephone interview was conducted to assess the clinical endpoints death, myocardial infarction, stent thrombosis, target 
lesion revascularization, target vessel revascularization, non-target vessel revascularization and stroke.
results: The median follow-up was 5.0 years (interquartile range 4.2 to 5.2). The incidence of all-cause death was 16.7% (n = 20) in the Yukon 
Choice versus 13.9% (n = 16) in the Taxus Liberté group (odds ratio [OR] 0.80; 95% confidence interval [CI] = 0.39 to 1.63; p = 0.67). Definite or 
presumed cardiovascular death occurred in 7.5% (n = 9) in the Yukon Choice and 8.6% (n = 10) in the Taxus Liberté group, respectively (OR 1.16; CI 
= 0.46 to 2.98; p = 0.94).There were no significant differences in the rates of myocardial infarction (9.2% versus 7.8%; OR 0.83; CI = 0.33 to 2.09; 
p = 0.88), definite stent thrombosis (0.8% versus 0.9%; OR 1.04; CI = 0.06 to 16.74; p = 1.0), target lesion revascularization (15% versus 15.5%; 
OR 1.04; CI = 0.51 to 2.12; p = 1.0), target vessel revascularization (18.3% versus 23.3%; OR 1.35; CI = 0.72 to 2.54; p = 0.44), non-target vessel 
revascularization (18.3% versus 26.7%; OR 1.63; CI = 0.88 to 3.02; p = 0.17) and stroke (3.3% versus 4.3%; OR 1.31; CI = 0.34 to 4.99; p = 0.96) 
between patients assigned to the Yukon Choice and the Taxus Liberté stent.
conclusion: At 5 years of follow-up, clinical outcome was similar between the polymer-free sirolimus-eluting Yukon Choice stent and the polymer-
based paclitaxel-eluting Taxus Liberté stent.
